top of page

Skin 101 Scar and Stretch Marks Cream

Scar 101

How are scars formed?


Scars are usually formed from a trauma or injury. This can be the result of surgery, a burn or an accident. Anything that causes the skin to break will cause a scar, and in some people the scars will get better. In a large proportion of people, the scars will remain red and raised and these need to be treated with a safe effective product that is clinically proven work. Some people heal slower than others and they are more likely to get scars.

​What are the different types of scars?

These scars are usually indented and result from acne or chicken pox. These scars are notoriously difficult to treat and most of the non-medical grade silicone gels on the market will not be effective against these scars. 


The majority of burns will cause scars as they tend to heal slower than most other types of wounds. Burn scars are actually hypertrophic scars. Early treatment is recommended and the use of silicone scar gel plus massage normally produces the best outcome.

The majority of people that scar develop Hypertrophic scars. These are red and raised, generally along the length of the injury.


Keloids are a different type of scar to the above and tend to be harder to treat. Keloids are normally formed after a trauma or wound, but spread away from the original wound. Very light skin and very dark skin tend to be more prone to Keloids and it is believed to be a genetic link to the formation of keloids.

If the scar is still red and raised after 2 weeks then the medical grade silicone scar gel should be used to reduce the redness and flatten the scars. It is critical if the patients scar easily or have family members that scar. Early use of medical grade silicone gel as soon as the skin has healed has been clinically proven to prevent scar formation.

scar treatment.png

Important Tips:


  • All scars get worse in the sun. As humans, it’s difficult to completely avoid the sun so do your best and always apply SPF30+ sunscreen and/or cover your score as much as possible if concerned with your scar.

  • As well as using ScarMD® Scar Gel & Spray, massage the scar with a simple moisturizing cream. Use a simple cream with no perfumes or additives in.

  • Don’t massage ScarMD® Scar Gel & Spray into the area. Apply a thin layer and leave it to dry.

  • If you have a history of scarring then use ScarMD® Scar Gel & Spray as soon as the wound has healed. Early use of ScarMD® Scar Gel has been proven to reduce the chance of scars developing by up to 60%.5

  • If you think that you have a Keloid scar then speak to a Dermatologist, Plastic Surgeon or Scar Specialist, who will advise the best combination treatments to use with ScarMD® Scar Gel & Spray.

Stretch Mark 101

Stretch Mark 101

How are Stretch Marks Formed?


Stretch Marks, or Stria Distensae in the medical community, a natural skin condition afflicting both men and women. Thankfully, stretch marks rarely cause serious health issues; however, those of us with stretch marks know very well the stress, psychological harm and discomfort stretch marks pose. While the exact cause of how or why stretch marks develop is undergoing extensive research, the factors that cause these unsightly marks are still poorly understood. Various theories exist, ranging from rapid stretching of the dermis (i.e. rapid weight gain during pregnancy or body building), growth spurts during puberty in adolescents, increase in certain hormones, others pose genetics may play a role and some scientists even propose stretch marks can result from infection.

Naturally women try to avoid them, investing a lot of time, energy and money to prevent and treat stretch marks. Our mission here at AIM Medical® is to provide women and men the best, highest quality and most effective scar prevention and therapy products, restoring your confidence and your skin.




pregnancy stretch mark



rapid weight gain stretch mark



puberty stretch mark



family history stretch mark

stretch mark.png

​Uncontrollable Risk Factors:

  • Skin Type – your risk is higher if you have fair skin

  • Family History – your risk is higher if stretch marks run in your family

  • Prior History – your risk is higher if you had prior stretch marks during puberty


Controllable Risk Factors:

  • Dermis Hydration State: – the overall health of the dermis significantly impacts your risk of stretch marks

  • Weight Gain – your risk is lower if you avoid excessive weight gain during pregnancy

  • Hydration – your risk is lower if you drink eight glasses of water each day

Eczema 101

Eczema 101

What is Eczema?

Eczema (also known as Atopic Dermatitis) is inflammation of the skin, typically characterized by itchiness, redness and a rash. It's common in children but can occur at any age. Atopic dermatitis is long lasting (chronic) and tends to flare periodically. It may be accompanied by asthma or hay fever.

Cause, Diagnosis and Cure

The cause of eczema is unknown but is presumed to be a combination of genetic and environmental factors. In some children, food allergies may play a role in causing eczema. Healthy skin helps retain moisture and protects you from bacteria, irritants and allergens. Eczema is related to a gene variation that affects the skin's ability to provide this protection. This allows your skin to be affected by environmental factors, irritants and allergens.

Hand Eczema

Hand Eczema

Leg Eczema

Leg Eczema

Infantile Atopic Dermatitis

Infantile Atopic Dermatitis

Toe Eczema

Toe Eczema

Arm Eczema

Arm Eczema

Diagnosis of eczema is based mostly on the history and physical examination. In uncertain cases, skin biopsy may be taken for a histopathologic diagnosis of dermatitis. Those with eczema may be especially prone to misdiagnosis of food allergies.


No cure has been found for eczema. But treatments and self-care measures can relieve itching and prevent new outbreaks. Treatment of atopic dermatitis is typically with moisturizers and steroid creams. Non-steroid creams are always preferred given the potentially severe side effects caused by steroid. Antibiotics may be required if there are signs of skin infection. Contact dermatitis is typically treated by avoiding the allergen or irritant.


Majority of the eczema treatments aim to control symptoms by reducing inflammation and relieving itching.



Bathing once or more a day is recommended, usually for five to ten minutes in warm water. Soaps should be avoided, as they tend to strip the skin of natural oils and lead to excessive dryness. There has not been adequate evaluation of changing the diet to reduce eczema. There is some evidence that infants with an established egg allergy may have a reduction in symptoms if eggs are eliminated from their diets.



Evidence indicates that moisturizing agents (emollients) may reduce eczema severity and lead to fewer flares. Some moisturizers or barrier creams may reduce irritation in occupational irritant eczema, a skin disease that can affect people in jobs that regularly come into contact with water, detergents, chemicals or other irritants. Some emollients may reduce the number of flares in people with dermatitis.



If symptoms are well controlled with moisturizers, steroids may only be required when flares occur. Corticosteroids are effective in controlling and suppressing symptoms in most cases. Once daily use is generally enough. While these usually bring about rapid improvements, they have greater side effects.


When eczema is severe and does not respond to other forms of treatment, systemic immunosuppressants are sometimes used. Immunosuppressants can cause significant side effects and some require regular blood tests. The most commonly used are ciclosporin, azathioprine, and methotrexate.


Long term use of topical steroids may result in skin atrophy, stria, telangiectasia. Their use on delicate skin (face or groin) is therefore typically with caution.

Light therapy

Light therapy using ultraviolet light has tentative support but the quality of the evidence is not very good. A number of different types of light may be used including UVA and UVB; in some forms of treatment, light sensitive chemicals such as psoralen are also used. Overexposure to ultraviolet light carries its own risks, particularly that of skin cancer.

Seborrhoea 101

Seborrhoea 101

What is Seborrhoea?

Seborrhoea (Seborrhoeic Dermatitis) is a long-term skin disorder. Symptoms include red, scaly, greasy, itchy, and inflamed skin. Areas of the skin rich in oil-producing glands are often affected including the scalp, face, and chest. It can result in social or self-esteem problems. In babies, when the scalp is primarily involved, it is called cradle cap. Dandruff is a milder form of the condition without inflammation.

Face Seborrheic Dermatitis
Head Seborrhoeic Dermatitis
Hair Seborrhoea

Symptoms and Causes

Seborrhoea's symptoms appear gradually, and usually the first signs are flaky skin and scalp. Symptoms occur most commonly anywhere on the skin of the scalp, behind the ears, on the face, and in areas where the skin folds. Flakes may be yellow, white or grayish. Redness and flaking may also occur on the skin near the eyelashes, on the forehead, around the sides of the nose, on the chest, and on the upper back.


In more severe cases, yellowish to reddish scaly pimples appear along the hairline, behind the ears, in the ear canal, on the eyebrows, on the bridge of the nose, around the nose, on the chest, and on the upper back. Commonly, patients experience mild redness, scaly skin lesions and in some cases hair loss. Other symptoms include patchy scaling or thick crusts on the scalp, red, greasy skin covered with flaky white or yellow scales, itching, soreness and yellow or white scales that may attach to the hair shaft. Seborrhoeic dermatitis can occur in infants younger than three months and it causes a thick, oily, yellowish crust around the hairline and on the scalp. Itching is not common among infants. Frequently, a stubborn diaper rash accompanies the scalp rash.

The cause of seborrhoeic dermatitis has not been fully clarified. The condition is thought to be due to a local inflammatory response to over-colonization by Malassezia fungi species in sebum-producing skin areas including the scalp, face, chest, back, underarms, and groin. Although Malassezia appears to be the central predisposing factor in seborrhoeic dermatitis, it is thought that other factors are necessary for the presence of Malassezia to result in the pathology characteristic of the condition. This is based on the fact that summer growth of Malassezia in the skin alone do not result in seborrhoeic dermatitis. Besides antifungals, the effectiveness of anti-inflammatory drugs, which reduce inflammation, and antiandrogens, which reduce sebum production, provide further insights into the pathophysiology of seborrhoeic dermatitis. In addition to the presence of Malassezia, genetic, environmental, hormonal, and immune-system factors are necessary for and/or modulate the expression of seborrhoeic dermatitis.



Proper medications are able to reduce symptoms of seborrhoeic dermatitis. These include certain antifungals, anti-inflammatory agents like corticosteroids and nonsteroidal anti-inflammatory drugs, antiandrogens, and antihistamines, among others.

Long term use of topical steroids may result in skin atrophy, stria, telangiectasia. Their use on delicate skin (face or groin) is therefore typically with caution.


  • Fulton JE., Jr Silicone gel sheeting for the prevention and management of evolving hypertrophic and keloid scars. Dermatol Surg. 1995;21:947–51.

  • Mustoe TA, et al. International clinical recommendations on scar management. Plast Reconstr Surgery. 2002;110:560–71.

  • Durani P, Bayat A. Levels of evidence for the treatment of keloid disease. J Plast Reconstr Aesthet Surg. 2008;61:4–17.

  • Plastic and Reconstructive Surgery September 15, 2005;Volume 116;Issue 4;pp: 1013-1020; A Randomized, Placebo-Controlled, Double-Blind, Prospective Clinical Trial of Silicone Gel in Prevention of Hypertrophic Scar Development in Median Sternotomy Wound

  • Dermatol Surg. 2001 Jul;27(7):641-4.;Prevention of hypertrophic scars and keloids by the prophylactic use of topical silicone gel sheets following a surgical procedure in an office setting.

  • Elsaie, E. MD, Baumann, S. MD, Elsaaiee L. MD, 2009. Striae Distensae (Stretch Marks) and Different Modalities of Therapy: An Update. Dermatol Surg 2009;35:563-573.

  • Elsaie, E. MD, Baumann, S. MD, Elsaaiee L. MD, 2009. Striae Distensae (Stretch Marks) and Different Modalities of Therapy: An Update. Dermatol Surg 2009;35:563-573.

  • Chang AL, Agredano YZ, Kimball AB. Risk factors associated with striae gravidarum. Journal of the American Academy of Dermatology.2004;51(6):881-5

  • Atwal GS, Manku LK, Griffiths CE, Polson DW. Striae gravidarum in primiparae. British Journal of Dermatology. 2006;155(5):965-9.

  • J-Orh R, Titapant V, Chuenwattana P, Tontisirin P. Prevalence and associated factors for striae gravidarum. Journal of the Medical Association of Thailand.2008;91(4):445-51.

  • Osman H, Rubeiz N, Tamim H, Nassar AH. Risk factors for the development of striae gravidarum. American Journal of Obstetrics and Gynecology. 2007;196(1):62.e1-5.

  • Mallol, J., Belda, M.A. et al. 1990. Prophylaxis of Striae gravidarum with a ttopical formulation. A double blind trial. International Journal of Cosmetic Science. 13:51-57.

  •  Nedorost, Susan T. (2012). Generalized Dermatitis in Clinical Practice. Springer Science & Business Media. pp. 1–3, 9, 13–14. ISBN 9781447128977. Archived from the original on 15 August 2016. Retrieved 29 July 2016.

  • ^ Jump up to:a b c d e f g h i j k l m "Handout on Health: Atopic Dermatitis (A type of eczema)". NIAMS. May 2013. Archived from the original on 30 May 2015. Retrieved 29 July 2016.

  • ^ Ferri, Fred F. (2010). Ferri's differential diagnosis : a practical guide to the differential diagnosis of symptoms, signs, and clinical disorders(2nd ed.). Philadelphia, PA: Elsevier/Mosby. p. Chapter D. ISBN 978-0323076999.

  • ^ Jump up to:a b c d e f g h i j k l m n o p q r s t u McAleer MA, Flohr C, Irvine AD (July 2012). "Management of difficult and severe eczema in childhood"(PDF). BMJ. 345: e4770. doi:10.1136/bmj.e4770. hdl:2262/75991. PMID 22826585. S2CID 36038433.

  • ^ Jump up to:a b Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. (GBD 2015 Disease and Injury Incidence and Prevalence Collaborators) (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.

  • ^ Habif (2015). Clinical Dermatology (6 ed.). Elsevier Health Sciences. p. 171. ISBN 9780323266079. Archived from the original on 17 August 2016. Retrieved 5 July 2016.

  • ^ Mowad CM, Anderson B, Scheinman P, Pootongkam S, Nedorost S, Brod B (June 2016). "Allergic contact dermatitis: Patient management and education". Journal of the American Academy of Dermatology. 74(6): 1043–54. doi:10.1016/j.jaad.2015.02.1144. PMID 27185422.

  • ^ Lurati AR (February 2015). "Occupational risk assessment and irritant contact dermatitis". Workplace Health & Safety. 63 (2): 81–7, quiz 88. doi:10.1177/2165079914565351. PMID 25881659. S2CID 40077567.

  • ^ Adkinson, N. Franklin (2014). Middleton's allergy : principles and practice (8 ed.). Philadelphia: Elsevier Saunders. p. 566. ISBN 9780323085939. Archived from the original on 15 August 2016.

  • ^ Wilkinson, Mark; Orton, David (2016). "Allergic Contact Dermatitis". In Barker, Jonathan; Bleiker, Tanya O.; Chalmers, Robert; Creamer, Daniel (eds.). Rook's Textbook of Dermatology (9 ed.). John Wiley & Sons. p. 128.4. ISBN 9781118441176. Archived from the original on 15 August 2016. Retrieved 29 July 2016.

  • ^ Frosch, Peter J. (2013). Textbook of Contact Dermatitis (2 ed.). Berlin, Heidelberg: Springer Berlin Heidelberg. p. 42. ISBN 9783662031049. Archived from the original on 16 August 2016.

  • ^ Caproni M, Antiga E, Melani L, Fabbri P (June 2009). "Guidelines for the diagnosis and treatment of dermatitis herpetiformis". Journal of the European Academy of Dermatology and Venereology. 23 (6): 633–8. doi:10.1111/j.1468-3083.2009.03188.x. PMID 19470076. S2CID 7906559.

  • ^ "Neurodermatitis (lichen simplex)". DermNet New Zealand Trust. 2017. Archived from the original on 2 February 2017. Retrieved 29 January 2017.

  • ^ "Neurodermatitis". Mayo Clinic. 2015. Archived from the original on 16 June 2010. Retrieved 6 November 2010.

  • ^ "Periorificial dermatitis". DermNet New Zealand Trust. 2017. Archived from the original on 2 February 2017. Retrieved 29 January2017.

  • ^ "Dermatitis herpetiformis". DermNet New Zealand Trust. 2017. Archived from the original on 2 February 2017. Retrieved 29 January2017.

  • ^ "Seborrheic dermatitis". DermNet New Zealand Trust. 2017. Archived from the original on 2 February 2017. Retrieved 29 January2017.

  • ^ "Seborrheic Dermatitis". Merck Manual, Consumer Version.

  • ^ Bufford JD, Gern JE (May 2005). "The hygiene hypothesis revisited". Immunology and Allergy Clinics of North America. 25 (2): 247–62, v–vi. doi:10.1016/j.iac.2005.03.005. PMID 15878454.

  • ^ Carswell F, Thompson S (July 1986). "Does natural sensitisation in eczema occur through the skin?". Lancet. 2 (8497): 13–5. doi:10.1016/S0140-6736(86)92560-2. PMID 2873316. S2CID 23111491.

  • ^ Henszel Ł, Kuźna-Grygiel W (2006). "[House dust mites in the etiology of allergic diseases]". Annales Academiae Medicae Stetinensis (in Polish). 52 (2): 123–7. PMID 17633128.

  • ^ Atopic Dermatitis at eMedicine

  • ^ Paternoster L, Standl M, Chen CM, Ramasamy A, Bønnelykke K, Duijts L, et al. (December 2011). "Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis". Nature Genetics. 44 (2): 187–92. doi:10.1038/ng.1017. PMC 3272375. PMID 22197932.

  • ^ Caproni M, Bonciolini V, D'Errico A, Antiga E, Fabbri P (2012). "Celiac disease and dermatologic manifestations: many skin clue to unfold gluten-sensitive enteropathy". Gastroenterology Research and Practice. Hindawi Publishing Corporation. 2012: 952753. doi:10.1155/2012/952753. PMC 3369470. PMID 22693492.

  • ^ Ciacci C, Cavallaro R, Iovino P, Sabbatini F, Palumbo A, Amoruso D, et al. (June 2004). "Allergy prevalence in adult celiac disease". The Journal of Allergy and Clinical Immunology. 113 (6): 1199–203. doi:10.1016/j.jaci.2004.03.012. PMID 15208605.

  • ^ Allam JP, Novak N (January 2006). "The pathophysiology of atopic eczema". Clinical and Experimental Dermatology. 31 (1): 89–93. doi:10.1111/j.1365-2230.2005.01980.x. PMID 16309494. S2CID 9812727.

  • ^ Ulf D, Eyerich K, Ring J (October 2007). "Eczema Pathophysiology - World Allergy Organization". Archived from the original on 2 February 2017. Retrieved 28 January 2017.

  • ^ "Eczema". University of Maryland Medical Center. Archived from the original on 27 July 2016.

  • ^ Atkins D (March 2008). "Food allergy: diagnosis and management". Primary Care. 35 (1): 119–40, vii. doi:10.1016/j.pop.2007.09.003. PMID 18206721.

  • ^ Johansen JD, Frosch PJ, Lepoittevin J (29 September 2010). Contact Dermatitis. ISBN 9783642038273. Archived from the original on 5 July 2014. Retrieved 21 April 2014.

  • ^ Fisher AA (2008). Fisher's Contact Dermatitis. ISBN 9781550093780. Retrieved 21 April 2014.

  • ^ Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, et al. (September 2001). "A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force". Allergy. 56 (9): 813–24. doi:10.1034/j.1398-9995.2001.t01-1-00001.x. PMID 11551246.

  • ^ Jump up to:a b Alsaad KO, Ghazarian D (December 2005). "My approach to superficial inflammatory dermatoses". Journal of Clinical Pathology. 58(12): 1233–41. doi:10.1136/jcp.2005.027151. PMC 1770784. PMID 16311340.

  • ^ "Eczema". ACP medicine. Archived from the original on 10 January 2014. Retrieved 9 January 2014.

  • ^ Bershad SV (November 2011). "In the clinic. Atopic dermatitis (eczema)". Annals of Internal Medicine. 155 (9): ITC51–15, quiz ITC516. doi:10.7326/0003-4819-155-9-201111010-01005. PMID 22041966. S2CID 207536375.

  • ^ ICD 10: Diseases of the skin and subcutaneous tissue (L00-L99) – Dermatitis and eczema (L20-L30) Archived 9 January 2014 at the Wayback Machine

  • ^ Ring J, Przybilla B, Ruzicka T (2006). Handbook of atopic eczema. Birkhäuser. p. 4. ISBN 978-3-540-23133-2. Retrieved 4 May 2010.

  • ^ Atopic Dermatitis National Eczema Association.

  • ^ "Balsam of Peru contact allergy". 28 December 2013. Archived from the original on 5 March 2014. Retrieved 5 March2014.

  • ^ Jump up to:a b c Greer FR, Sicherer SH, Burks AW (April 2019). "The Effects of Early Nutritional Interventions on the Development of Atopic Disease in Infants and Children: The Role of Maternal Dietary Restriction, Breastfeeding, Hydrolyzed Formulas, and Timing of Introduction of Allergenic Complementary Foods". Pediatrics. 143 (4): e20190281. doi:10.1542/peds.2019-0281. PMID 30886111.

  • ^ Kalliomäki M, Antoine JM, Herz U, Rijkers GT, Wells JM, Mercenier A (March 2010). "Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of allergic diseases by probiotics". The Journal of Nutrition. 140 (3): 713S–21S. doi:10.3945/jn.109.113761. PMID 20130079.

  • ^ "DoD Details Military Smallpox Vaccination Program". Retrieved 10 January 2019.

  • ^ "CDC Smallpox | Smallpox (Vaccinia) Vaccine Contraindications (Info for Clinicians)". 7 February 2007. Archived from the original on 25 January 2010. Retrieved 7 February 2010.

  • ^ "Coping with atopic dermatitis". 2017. Retrieved 11 September 2017.

  • ^ Gutman AB, Kligman AM, Sciacca J, James WD (December 2005). "Soak and smear: a standard technique revisited". Archives of Dermatology. 141 (12): 1556–9. doi:10.1001/archderm.141.12.1556. PMID 16365257.

  • ^ "Atopic dermatitis: Bleach bath therapy". Retrieved 4 May 2020.

  • ^ Jump up to:a b c d Bath-Hextall F, Delamere FM, Williams HC (January 2008). Bath-Hextall FJ (ed.). "Dietary exclusions for established atopic eczema". The Cochrane Database of Systematic Reviews (1): CD005203. doi:10.1002/14651858.CD005203.pub2. PMC 6885041. PMID 18254073. Archived from the original on 21 October 2013.

  • ^ Jump up to:a b Institute for Quality and Efficiency in Health Care. "Eczema: Can eliminating particular foods help?". Informed Health Online. Institute for Quality and Efficiency in Health Care. Archived from the original on 21 October 2013. Retrieved 24 June 2013.

  • ^ Ricci G, Patrizi A, Bellini F, Medri M (2006). Use of textiles in atopic dermatitis: care of atopic dermatitis. Current Problems in Dermatology. 33. pp. 127–43. doi:10.1159/000093940. ISBN 978-3-8055-8121-9. PMID 16766885.

  • ^ Nankervis H, Pynn EV, Boyle RJ, Rushton L, Williams HC, Hewson DM, Platts-Mills T (January 2015). "House dust mite reduction and avoidance measures for treating eczema". The Cochrane Database of Systematic Reviews. 1: CD008426. doi:10.1002/14651858.CD008426.pub2. hdl:10044/1/21547. PMID 25598014.

  • ^ van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BW (February 2017). "Emollients and moisturisers for eczema". The Cochrane Database of Systematic Reviews. 2: CD012119. doi:10.1002/14651858.CD012119.pub2. PMC 6464068. PMID 28166390.

  • ^ Jungersted JM, Agner T (August 2013). "Eczema and ceramides: an update". Contact Dermatitis. 69 (2): 65–71. doi:10.1111/cod.12073. PMID 23869725. S2CID 9471706.

  • ^ Jump up to:a b Bauer A, Rönsch H, Elsner P, Dittmar D, Bennett C, Schuttelaar ML, et al. (April 2018). "Interventions for preventing occupational irritant hand dermatitis" (PDF). The Cochrane Database of Systematic Reviews. 4: CD004414. doi:10.1002/14651858.CD004414.pub3. PMC 6494486. PMID 29708265. Archived from the original (PDF) on 6 March 2020. Retrieved 26 June 2019.

  • ^ van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BW (February 2017). "Emollients and moisturisers for eczema". The Cochrane Database of Systematic Reviews. 2: CD012119. doi:10.1002/14651858.CD012119.pub2. PMC 6464068. PMID 28166390.

  • ^ Hoare C, Li Wan Po A, Williams H (2000). "Systematic review of treatments for atopic eczema". Health Technology Assessment. 4 (37): 1–191. doi:10.3310/hta4370. PMC 4782813. PMID 11134919. Archived from the original on 7 February 2009. Retrieved 18 November2009.

  • ^ Bewley A (May 2008). "Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids". The British Journal of Dermatology. 158 (5): 917–20. doi:10.1111/j.1365-2133.2008.08479.x. PMID 18294314. S2CID 46445371.

  • ^ Oakley, M.D., Amanda. "Topical corticosteroid withdrawal". DermNet NZ. DermNet New Zealand Trust. Archived from the original on 16 March 2016.

  • ^ Apfelbacher CJ, van Zuuren EJ, Fedorowicz Z, Jupiter A, Matterne U, Weisshaar E (February 2013). "Oral H1 antihistamines as monotherapy for eczema". The Cochrane Database of Systematic Reviews (2): CD007770. doi:10.1002/14651858.CD007770.pub2. PMC 6823266. PMID 23450580.

  • ^ Jump up to:a b Matterne U, Böhmer MM, Weisshaar E, Jupiter A, Carter B, Apfelbacher CJ (January 2019). "Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema". The Cochrane Database of Systematic Reviews. 1: CD012167. doi:10.1002/14651858.CD012167.pub2. PMC 6360926. PMID 30666626.

  • ^ Shams K, Grindlay DJ, Williams HC (August 2011). "What's new in atopic eczema? An analysis of systematic reviews published in 2009-2010". Clinical and Experimental Dermatology. 36 (6): 573–7, quiz 577–8. doi:10.1111/j.1365-2230.2011.04078.x. PMID 21718344. S2CID 42321918.

  • ^ Carr WW (August 2013). "Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations". Paediatric Drugs. 15 (4): 303–10. doi:10.1007/s40272-013-0013-9. PMC 3715696. PMID 23549982.

  • ^ "Atopic eczema - Treatment". NHS Choices, London, UK. 12 February 2016. Archived from the original on 16 January 2017. Retrieved 27 January 2017.

  • ^ Jump up to:a b "Medication Guide. Elidel® (pimecrolimus) Cream, 1%" (PDF). US Food and Drug Administration. March 2014. Archived (PDF) from the original on 11 February 2017. Retrieved 27 January 2017.

  • ^ Torley D, Futamura M, Williams HC, Thomas KS (July 2013). "What's new in atopic eczema? An analysis of systematic reviews published in 2010-11". Clinical and Experimental Dermatology. 38 (5): 449–56. doi:10.1111/ced.12143. PMID 23750610. S2CID 24638685.

  • ^ Sawangjit, Ratree; Dilokthornsakul, Piyameth; Lloyd-Lavery, Antonia; Lai, Nai Ming; Dellavalle, Robert; Chaiyakunapruk, Nathorn (14 September 2020). "Systemic treatments for eczema: a network meta-analysis". Cochrane Database of Systematic Reviews. 9: CD013206. doi:10.1002/14651858.cd013206.pub2. ISSN 1465-1858. PMID 32927498.

  • ^ Gambichler T (March 2009). "Management of atopic dermatitis using photo(chemo)therapy". Archives of Dermatological Research. 301 (3): 197–203. doi:10.1007/s00403-008-0923-5. PMID 19142651. S2CID 29045951.

  • ^ Meduri NB, Vandergriff T, Rasmussen H, Jacobe H (August 2007). "Phototherapy in the management of atopic dermatitis: a systematic review". Photodermatology, Photoimmunology & Photomedicine. 23(4): 106–12. doi:10.1111/j.1600-0781.2007.00291.x. PMID 17598862. S2CID 25684608.

  • ^ Stöppler MC (31 May 2007). "Psoriasis PUVA Treatment Can Increase Melanoma Risk". MedicineNet. Archived from the original on 29 September 2007. Retrieved 17 October 2007.

  • ^ Vieira BL, Lim NR, Lohman ME, Lio PA (December 2016). "Complementary and Alternative Medicine for Atopic Dermatitis: An Evidence-Based Review". American Journal of Clinical Dermatology(Review). 17 (6): 557–581. doi:10.1007/s40257-016-0209-1. PMID 27388911. S2CID 35460522.

  • ^ Jump up to:a b "Sulfur". University of Maryland Medical Center. 1 April 2002. Archived from the original on 5 August 2012. Retrieved 15 October2007.

  • ^ Armstrong NC, Ernst E (August 1999). "The treatment of eczema with Chinese herbs: a systematic review of randomized clinical trials". British Journal of Clinical Pharmacology. 48 (2): 262–4. doi:10.1046/j.1365-2125.1999.00004.x. PMC 2014284. PMID 10417508.

  • ^ Jump up to:a b Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams HC (February 2012). Bath-Hextall FJ (ed.). "Dietary supplements for established atopic eczema". The Cochrane Database of Systematic Reviews. 2 (2): CD005205. doi:10.1002/14651858.CD005205.pub3. PMC 6517242. PMID 22336810.

  • ^ Jump up to:a b Bamford JT, Ray S, Musekiwa A, van Gool C, Humphreys R, Ernst E (April 2013). Bamford JT (ed.). "Oral evening primrose oil and borage oil for eczema". The Cochrane Database of Systematic Reviews. 4 (4): CD004416. doi:10.1002/14651858.CD004416.pub2. PMID 23633319.

  • ^ Makrgeorgou A, Leonardi-Bee J, Bath-Hextall FJ, Murrell DF, Tang ML, Roberts A, Boyle RJ (November 2018). "Probiotics for treating eczema". The Cochrane Database of Systematic Reviews. 11: CD006135. doi:10.1002/14651858.CD006135.pub3. PMC 6517242. PMID 30480774.

  • ^ Eldred DC, Tuchin PJ (November 1999). "Treatment of acute atopic eczema by chiropractic care. A case study". Australasian Chiropractic & Osteopathy. 8 (3): 96–101. PMC 2051093. PMID 17987197.

  • ^ Ersser SJ, Cowdell F, Latter S, Gardiner E, Flohr C, Thompson AR, et al. (January 2014). "Psychological and educational interventions for atopic eczema in children". The Cochrane Database of Systematic Reviews (1): CD004054. doi:10.1002/14651858.CD004054.pub3. PMC 6457897. PMID 24399641.

  • ^ Barnes TM, Greive KA (November 2013). "Use of bleach baths for the treatment of infected atopic eczema". The Australasian Journal of Dermatology. 54 (4): 251–8. doi:10.1111/ajd.12015. PMID 23330843. S2CID 19644659.

  • ^ Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. (December 2012). "Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet. 380 (9859): 2163–96. doi:10.1016/S0140-6736(12)61729-2. PMC 6350784. PMID 23245607.

  • ^ Osman M, Hansell AL, Simpson CR, Hollowell J, Helms PJ (February 2007). "Gender-specific presentations for asthma, allergic rhinitis and eczema in primary care". Primary Care Respiratory Journal. 16 (1): 28–35. doi:10.3132/pcrj.2007.00006. PMC 6634172. PMID 17297524.

  • ^ Taylor B, Wadsworth J, Wadsworth M, Peckham C (December 1984). "Changes in the reported prevalence of childhood eczema since the 1939-45 war". Lancet. 2 (8414): 1255–7. doi:10.1016/S0140-6736(84)92805-8. PMID 6150286. S2CID 2842761.

  • ^ Simpson CR, Newton J, Hippisley-Cox J, Sheikh A (March 2009). "Trends in the epidemiology and prescribing of medication for eczema in England". Journal of the Royal Society of Medicine. 102 (3): 108–17. doi:10.1258/jrsm.2009.080211. PMC 2746851. PMID 19297652.

  • ^ Luckhaupt SE, Dahlhamer JM, Ward BW, Sussell AL, Sweeney MH, Sestito JP, Calvert GM (June 2013). "Prevalence of dermatitis in the working population, United States, 2010 National Health Interview Survey". American Journal of Industrial Medicine. 56 (6): 625–34. doi:10.1002/ajim.22080. PMID 22674651.

  • ^ Liddell HG, Scott R. "Ekzema". A Greek-English Lexicon. Tufts University: Perseus.

  • ^ Textbook of Atopic Dermatitis. Taylor & Francis. 1 May 2008. p. 1. ISBN 9780203091449. Archived from the original on 28 May 2016.

  • ^ "Definition of ECZEMA". Archivedfrom the original on 22 February 2016. Retrieved 15 February 2016.

  • ^ Jump up to:a b Center for Food Safety and Applied Nutrition (1 September 2020). ""Hypoallergenic" Cosmetics". FDA.

  • ^ Murphy LA, White IR, Rastogi SC (May 2004). "Is hypoallergenic a credible term?". Clinical and Experimental Dermatology. 29 (3): 325–7. doi:10.1111/j.1365-2230.2004.01521.x. PMID 15115531. S2CID 41482522.

  • ^ "Technical document on cosmetic claims". European Commission. Retrieved 7 December 2020.

  • ^ Kulliney, Kacey (6 September 2019). "EU 'free from' cosmetics claims technical document is guidance, not regulation: Expert". Retrieved 7 December 2020.

  • ^ Snast I, Reiter O, Hodak E, Friedland R, Mimouni D, Leshem YA (April 2018). "Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis". American Journal of Clinical Dermatology. 19 (2): 145–165. doi:10.1007/s40257-017-0324-7. PMID 29098604. S2CID 4220890.

  • ^ Lauffer F, Ring J (2016). "Target-oriented therapy: Emerging drugs for atopic dermatitis". Expert Opinion on Emerging Drugs. 21 (1): 81–9. doi:10.1517/14728214.2016.1146681. PMID 26808004. S2CID 207484890.

bottom of page